🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Glycopyrronium MDI

Found 58 matching trials

Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD

PHASE2

The overall objective of this study was to assess the efficacy and safety o...

Status

Completed

Location

Pearl Investigative Site

Start Date

2015-01-28

Trial ID

NCT03256552

Treatments Being Tested

Glycopyrronium MDI 28.8 micrograms Glycopyrronium MDI 14.4 micrograms Glycopyrronium MDI 7.2 micrograms Placebo MDI

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

PHASE1

The primary purpose of this study is to demonstrate the equivalence of bude...

Status

Withdrawn

Location

Multiple Locations

Start Date

2024-10-17

Trial ID

NCT06340581

Treatments Being Tested

Treatment A: BGF MDI HFA Treatment B: BGF MDI HFO Treatment C: BGF MDI HFO AeroChamber Plus Flow-Vu Spacer

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

The purpose of this study is to evaluate the efficacy of Fixed Combination ...

Status

Completed

Location

Medical Center Convex EOOD

Start Date

2018-06-15

Trial ID

NCT03590379

Treatments Being Tested

CHF 5993 DPI CHF5993 pMDI CHF 1535 pMDI Placebo DPI Placebo pMDI

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

PHASE3

This is a variable length study to evaluate the efficacy and safety of bude...

Status

Completed

Location

Research Site

Start Date

2021-03-01

Trial ID

NCT04609904

Treatments Being Tested

BGF MDI 320/28.8/9.6 μg BGF MDI 320/14.4/9.6 μg BFF MDI 320/9.6 μg BFF pMDI 320/9 μg

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

PHASE3

This is a randomized, double-blind, multi-center, parallel-group study to a...

Status

Completed

Location

Research Site

Start Date

2015-06-30

Trial ID

NCT02465567

Treatments Being Tested

BGF MDI 320/14.4/9.6 μg GFF MDI 14.4/9.6 μg BGF MDI 160/14.4/9.6 μg BFF MDI 320/9.6 μg

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

PHASE3

A Randomized, Double-Blind, Parallel Group, 28-Week Chronic Dosing, Multi-C...

Status

Completed

Location

Research Site

Start Date

2016-08-09

Trial ID

NCT03262012

Treatments Being Tested

BGF MDI (PT010)GFF MDI (PT003)BFF MDI (PT009)Symbicort® Turbohaler® Inhalation Powder

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

PHASE1

The study is being conducted to compare the pharmacokinetic (PK) of BDP (an...

Status

Completed

Location

SGS Belgium NV - Clinical Pharmacology Unit

Start Date

2023-04-24

Trial ID

NCT05898984

Treatments Being Tested

Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

PHASE3

This study will investigate the effect of Budesonide, Glycopyrronium, and F...

Status

Completed

Location

Research Site

Start Date

2023-10-24

Trial ID

NCT06067828

Treatments Being Tested

Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate Treatment B: Budesonide and Formoterol Fumarate Treatment C : Placebo

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

PHASE4

Double Blind, Multinational, Multicentre, Randomised, Placebo-Controlled, 3...

Status

Completed

Location

PAREXEL International GmbH Early Phase Clinical Unit Berlin

Start Date

2021-10-28

Trial ID

NCT05097014

Treatments Being Tested

CHF5993 CHF1535 Matched placebo

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

PHASE3

This is a 12-week (with an extension to 52 weeks in a subset of participant...

Status

Completed

Location

Research Site

Start Date

2022-09-27

Trial ID

NCT05573464

Treatments Being Tested

BGF MDI HFO 320/14.4/9.6 μg BGF MDI HFA 320/14.4/9.6 μg

Previous Next